AN2 Therapeutics (NASDAQ:ANTX) stock is taking a beating on Friday after the company provided an update on its EBO-301 Phase 2/3 study.AN2 Therapeutics notes that information comes from the Phase 2 study of epetraborole as an optimized background regimen (OBR) in treatment-refractory MAC lung disease. That includes it meeting its primary endpoint but failing to meet a key secondary endpoint.On top of that, the company notes that it stopped accepting new patients to the Phase 3 part of the study in February. ...